Legalize59765 laws
59765 laws
- § 333a. Repealed. [Pub. L. 101–647, title XIX, § 1905](/us/pl/101/647/tXIX/s1905), Nov. 29, 1990, [104 Stat. 4853](/us/stat/104/4853)
- § 334. Seizure
- § 343a. Repealed. [Pub. L. 106–554, § 1(a)(1) [title V, § 517]](/us/pl/106/554/s1/a/1/tV/s517), Dec. 21, 2000, [114 Stat. 2763](/us/stat/114/2763), 2763A–73
- § 343–1. National uniform nutrition labeling
- § 343–2. Dietary supplement labeling exemptions
- § 343–3. Disclosure
- § 344. Emergency permit control
- § 345. Regulations making exemptions
- § 346. Tolerances for poisonous or deleterious substances in food; regulations
- § 346a. Tolerances and exemptions for pesticide chemical residues
- § 346b. Authorization of appropriations
- § 347. Intrastate sales of colored oleomargarine
- § 347a. Congressional declaration of policy regarding oleomargarine sales
- § 355. New drugs
- § 355a. Pediatric studies of drugs
- § 355c. Research into pediatric uses for drugs and biological products
- § 355c–1. Report
- § 355d. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers
- § 355f. Extension of exclusivity period for new qualified infectious disease products
- § 355g. Utilizing real world evidence
- § 355h. Regulation of certain nonprescription drugs that are marketed without an approved drug application
- § 1480. Repealed. [Pub. L. 89–554, § 8(a)](/us/pl/89/554/s8/a), Sept. 6, 1966, [80 Stat. 657](/us/stat/80/657), 658
- § 356g. Standards for regenerative medicine and regenerative advanced therapies
- § 356h. Competitive generic therapies
- § 356j. Discontinuance or interruption in the production of medical devices
- § 356l. Advanced manufacturing technologies designation program
- § 356–1. Accelerated approval of priority countermeasures
- § 356–2. Accelerated approval Council
- § 357. Qualification of drug development tools
- § 358. Authority to designate official names
- § 359. Nonapplicability of subchapter to cosmetics
- § 360. Registration of producers of drugs or devices
- § 360bbb–1. Dispute resolution
- § 360bbb–2. Classification of products
- § 360bbb–3. Authorization for medical products for use in emergencies
- § 360bbb–3a. Emergency use of medical products
- § 360bbb–3b. Products held for emergency use
- § 360bbb–3c. Expedited development and review of medical products for emergency uses
- § 360bbb–4. Countermeasure development, review, and technical assistance
- § 360bbb–4a. Priority review to encourage treatments for agents that present national security threats
- § 360bbb–4b. Medical countermeasure master files
- § 360b–1. Priority zoonotic animal drugs
- § 360c. Classification of devices intended for human use
- § 360cc. Protection for drugs for rare diseases or conditions
- § 360ccc. Conditional approval of new animal drugs for minor use and minor species and certain new animal drugs
- § 360ccc–1. Index of legally marketed unapproved new animal drugs for minor species
- § 360ccc–2. Designated new animal drugs for minor use or minor species
- § 360c–1. Reporting
- § 360ee. Grants and contracts for development of drugs for rare diseases and conditions
- § 360eee. Definitions